As a pioneer in the field, the Mayo Clinic plays an integral role by discovering new tests and treatments for plasma cell disorders. Our algorithmic approach ensures that the right tests are ordered at the right time, and that health care providers get clinically actionable answers for their patients faster. And testing with Mayo Clinic means 24/7 access to our physician and laboratory experts, who are leaders in their field.
Testing for Plasma-Cell Proliferative Disorders [Brochure]
Society of Hematopathology Symposium Video
Plasma-Cell Neoplasms: Providing a Continuum of Care
For patients at risk of plasma cell disorders, early identification is critical to better outcomes. Coined as MASS-FIX, our innovative approach uses matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and marks the first major breakthrough in multiple myeloma screening since electrophoresis was developed in 1967.
By weighing M proteins, we overcome electrophoresis’s limitations in detection and provide the most accurate understanding of a patient’s M proteins. This novel testing also helps health care providers understand their patient’s risk of progression to multiple myeloma or AL amyloidosis. This level of insight is not possible via traditional testing methods.
Enhanced Test Panel for Monoclonal Gammopathy: Finding the Fingerprint
Screening and Monitoring of Monoclonal Gammopathies
[A Test in Focus]
mSMART uses the latest consensus criteria to determine a patient’s genetic risk of developing multiple myeloma to better inform individualized treatment plans.
The Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART) guides providers to the best treatment options. Our approach takes into account the fact that multiple myeloma is increasingly recognized as more than one disease, with cytogenic, molecular and proliferative heterogenity. While novel agents and combinations are rapidly redefining the treatment paradigm, patient outcomes vary based on risk stratification.
mSMART: Stratification for Myeloma and Risk-Adapted Therapy
Since the early 2000s, the average length of survival from time of diagnosis has more than tripled to more than five years.
The Most Accurate Testing for Monitoring
Arming providers with higher specificity than traditional immunofixation can improve care quality by avoiding unnecessary bone marrow biopsies in favor of monitoring and identifying multiple myeloma with a blood sample.
Our new methodology’s greater sensitivity and specificity identifies changes in patients’ M protein levels. MASS-FIX differentiates monoclonal therapeutic interference from a patient’s M protein spike.
Minimal Residual Disease Testing
Detecting minimal residual disease after therapy has become increasingly important. Patients who do not achieve a minimal residual disease (MRD) negative status will relapse faster and will relapse faster and have a shorter survival length.2
With a sensitivity of 10(-5), our EuroFlow MRD test meets the guidelines recommended by the International Myeloma Working Group (IMWG), the National Comprehensive Cancer Network (NCCN), and the International Clinical Cytometry Society. Additionally, because most clinical trials require the use of MRD testing with at least a 10(-5) sensitivity, approaches that overcome the current limitations of conventional flow cytometry must be used.
There are 36 distinct proteins known to cause amyloidosis, and the pathogenesis of each is unique. Treatment approaches therefore differ greatly based on the protein subtype causing the disease. Given the risks associated with amyloidosis and treatment, accurate typing is essential to timely, effective, and cost-efficient disease management.